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The physicochemical deposition of calcium-phosphate in the arterial wall is prevented
by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases
have shed light on the consequences of loss-of-function mutations for different
calcification inhibitors, and genetic targeting of these pathways in mice have generated
a clearer picture on the mechanisms involved. For example, generalized arterial
calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide
pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into
pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been
reinforced by the protective effects of PPi in various mouse models displaying ectopic
calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another
potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene
or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas
PPi and MGP represent locally produced calcification inhibitors, also systemic factors
contribute to protection against arterial calcification. One such example is Fetuin-A,
which is mainly produced in the liver and which forms calciprotein particles (CPPs),
inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their
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soft tissue deposition. Other calcification inhibitors with potential importance for arterial
calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present
review is to outline the latest insights into how different calcification inhibitors prevent
arterial calcification both under physiological conditions and in the case of disturbed
calcium-phosphate balance, and to provide a consensus statement on their potential
therapeutic role for arterial calcification.
Keywords: arterial calcification, pyrophosphate, gla proteins, klotho, osteoprotegerin, osteopontin, fetuin
Vascular calcification (VC) is a common occurrence in patients
affected with chronic diseases including diabetes, chronic kidney
disease (CKD), or atherosclerosis. VC is also a hallmark of rare
genetic diseases including pseudoxanthoma elasticum (PXE),
generalized arterial calcification of infancy (GACI), Keutel
syndrome, and progeria (1). Although the pathogenesis and
clinical significance of VC are dependent on the etiology,
the endpoint is invariably the formation of hydroxyapatite
(HA) deposits in the arterial wall. Over the last two decades,
studies have identified a number of calcification inhibitors
in the healthy vessel wall that act to protect the vascular
smooth muscle cells (VSMCs) from calcification. These factors
act by either directly interfering with molecular pathways
and/or sequestering hydroxyapatite components impairing their
assembly and deposition. Their actions also depend on the stage
of crystal formation and environmental context. Tremendous
efforts have been put into the understanding of the mechanisms
involved in the activity of these endogenous inhibitors that
represent attractive factors with therapeutic relevance to VC
treatment.
INORGANIC PYROPHOSPHATE
Inorganic pyrophosphate (PPi), which consists of two inorganic
phosphate molecules joined by a hydrolyzable ester, was first
recognized as a key endogenous inhibitor of biomineralization
in the 1960’s (2). The major source of PPi is extracellular
ATP, which is released from cells through a highly regulated
process (3). Subsequently, ATP can be rapidly hydrolyzed by
ecto-nucleotide pyrophosphatase/phosphodiesterases (eNPPs)
to produce PPi. Additionally, the membrane protein ANK
(progressive ankylosis or ANKH) regulates PPi levels through the
transport of intracellular PPi to the extracellular environment (4).
Furthermore, a crucial source of systemic PPi is provided through
ATP-binding cassette subfamily C member 6 (ABCC6)-mediated
ATP release from hepatocytes (5).
The formation of calcium phosphates and homogeneous
precipitation is not thermodynamically favored in blood and
solutions, but it still can take place through the nucleating activity
of matrix proteins such as collagen or elastin (6, 7). Nucleation
of amorphous calcium phosphate is prevented by PPi, which
also inhibits the crystallization toward hydroxyapatite and crystal
growth by binding to the hydroxyapatite surface (2, 8).
Reduced circulating PPi concentration is commonly present
during vascular calcification, as observed in hemodialysis
patients (9). PPi is hydrolyzed by local phosphatases, such as
tissue-non-specific alkaline phosphatase (TNAP). Consequently,
when the expression of TNAP is selectively increased, ectopic
calcification is observed (10). During CKD, aortic calcification
is accompanied by TNAP overexpression (11), an event
that precedes the first observed calcium nanodeposits and
hyperphosphatemia in a rat CKD model (12). In those, calcium
deposition is followed by an unexpected local increase in
ANKH expression and late increase in ENPP1 expression.
These expression changes are followed by reduced plasma
PPi concentrations as a later event (12). Therefore, the local
concentration of PPi may be a relevant factor for the initial
deposition of calcium in soft tissue, whereas reduced circulating
PPi levels may play a role during ESRD and hemodialysis.
A number of animal models have further contributed to
our understanding of the role of reduced PPi levels in VC.
Mice lacking ABCC6 (Abcc6−/−) display a 40% reduction in
plasma PPi levels (13) and present arterial calcification and
an enhanced myogenic response (14). Enpp1-knockout mice
also show depressed levels of circulating PPi, with concomitant
increased calcification in articular cartilage, peri-spinal ligament
and aorta (15). A comparable phenotype can be found in
the so-called tiptoe-walking (ttw/ttw) mouse (16), a naturally
occurring mutant with a non-sense mutation in Enpp1, and the
asj/asj mouse, which carries a V246D missense mutation (17).
Furthermore, a naturally occurring truncation mutation of the
C-terminal cytosolic domain of ANK appears to attenuate PPi
channeling in ank/ank mutant mice, which display VC (18).
Intriguingly, intraperitoneal administration of PPi in adenine-
induced uremic calcification reduced calcium content by 70%
(19), and a recent study has shown that orally administered PPi,
also inhibits arterial calcification in ttw/ttw and Abcc6−/− mice
(20), reinforcing the central role of PPi in the protection against
VC.
GLA PROTEINS
Matrix Gla protein (MGP) and Gla-rich protein (GRP),
also known as Upper zone of growth plate and Cartilage
Matrix Associated protein (UCMA) because of its original
discovery in cartilage chondrocytes, are small secreted matrix
proteins. They are members of the vitamin K-dependent
(VKD) protein family containing, in their mature forms, several
γ-carboxylated glutamate (Gla) residues. These VKD post-
translational modifications (5 in human MGP, 15 in human
GRP), enable MGP and GRP to bind calcium and calcified
matrices (21, 22), which can modulate their function (23, 24).
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Under normal physiological conditions, both MGP and
GRP are synthetized by a variety of cell types including
VSMCs and chondrocytes, where they function locally (21,
22). In agreement with this finding is the observation that
both carboxylated and uncarboxylated MGP are localized at
different levels in mineralized elastic fibers (25–27). Reverse
genetics has clearly shown that MGP is a potent physiological
inhibitor of calcification (28) since Mgp-deficient mice exhibit
lethal early spontaneous medial calcification of their arterial
trunk. Mutations in the human MGP gene cause Keutel
syndrome, a rare autosomal recessive disease characterized
by abnormal cartilage calcification, short stature, multiple
peripheral pulmonary stenoses, brachytelephalangia, and inner
ear deafness (29–31). However, in contrast to the mouse, humans
rarely develop arterial calcifications (32). This has been suggested
to be due to compensatory up-regulation of osteopontin (OPN,
see below) in the vessel wall, which may have a protective effect
in Keutel syndrome patients (33).
Interestingly, beside mutations, post-translational
modifications (i.e., γ-carboxylation and/or phosphorylation
for MGP) can further influence the clinical phenotype in
patients. For MGP, its dephosphorylated and uncarboxylated
form (dp-ucMGP) is a surrogate marker in CKD patients (34)
and is associated with increased incidence of cardiovascular
diseases (35, 36).
Several studies have also implicated GRP in vascular and soft
tissue calcification, osteoarthritis, inflammation and carcinoma
(37). Similar to MGP, GRP inhibits phosphate-induced VSMC
calcification via SMAD-dependent BMP signaling (38). However,
in contrast toMgp-deficient mice, GRP deletion does not induce
a clear phenotype (39), which contradicts a putative essential role
as a physiological calcification inhibitor in vivo.
FETUIN-A
Fetuin-A, also known as alpha2-Heremans-Schmid glycoprotein,
is a liver-derived protein, which was initially isolated from fetal
calf serum (40) and later also found in human serum (41, 42).
Fetuin-A is the strongest circulating proteinaceous calcification
inhibitor, being able to bind ∼100 Ca2+ ions per molecule,
i.e., ∼50x the calcium-binding capacity of an albumin molecule
(43). The Fetuin-A cystatin 1-domain contains a functional site,
which is able to bind clusters of amorphous calcium phosphate
(Ca9(PO4)6).
When pure Fetuin-A or Fetuin-A-containing serum is
exposed to high calcium and phosphate concentrations, mineral-
laden Fetuin-A molecules coalesce to form so-called primary
calciprotein particles (CPP) (44, 45). These particles contain
amorphous calcium phosphate and have a diameter of 50–
100 nm. In analogy to lipoprotein particles, which solubilize fatty
acids, CPP keep calcium phosphate in solution and prevent
it from precipitating (46). Over time, however, primary CPP
undergo spontaneous transformation toward secondary CPP,
which are larger (>100 nm), of elongate shape and contain
crystalline calcium phosphate (HA) (47). CPP can be regarded as
the nano-morphological correlate of a humoral mineral buffering
system in blood. Interestingly, both primary and secondary
CPP have been found in blood samples from patients with
CKD (48, 49). Recent work suggests that circulating CPP may
predominantly represent primary CPP or even earlier forms
(“low molecular weight CPP”) (50).
Consistent with the important calcification-inhibiting
properties of Fetuin-A, mice deficient in fetuin-A develop heavy
and diffuse soft tissue calcifications throughout the whole body
(51). In contrast, upon induction of vascular injury, calcifications
are primarily found in the intimal plaques, indicating an
interaction between systemic and local calcification facilitators
(51).
Fetuin-A is a negative acute phase protein, and, accordingly,
its blood concentrations are commonly lower in the presence
of inflammation (52). Furthermore, circulating Fetuin-A
concentrations have been found to be associated with SNPs in
the genetic region coding for the fetuin-A protein (53). Low
fetuin-A concentrations have also been found in CKD patients
and these low levels been associated with poor long-term
cardiovascular outcome (54). Recent data indicate that fetuin-A
should not be considered as an isolated factor only. In contrast, it
should rather be seen in the functional context of the formation
of mineral-fetuin-complexes/CPP and thus the performance of
the humoral mineral buffering system (55, 56). Specifically, a
newly developed blood test measures the transformation (T50-)
time point from primary to secondary CPP in vitro, and thus
the calcification homeostasis in blood beyond single factors.
This provides more insight and functional information about
the net effect of the humoral factors, which inhibit or promote
calcification (57–61). These recent findings have the potential to
vastly widen our view and to open new and exciting possibilities
for research and clinical care alike.
KLOTHO
Klotho is a single pass transmembrane protein that acts as a co-
receptor for fibroblast growth factor-23 (FGF23) (62). Signaling
through the Klotho and FGF receptor heterodimer decreases
both phosphate reabsorption, via down-regulation of the renal
proximal tubule type-II sodium phosphate co-transporters as
well as 1,25(OH)2 vitamin D synthesis. Thus, Klotho plays a
major role in calcium-phosphate equilibrium. Additionally, a
soluble form of Klotho, produced by alternative splicing and
cleavage by secretases, can be found in the circulation. This
soluble form acts as an endocrine factor exerting its functions by
its glycosidase activity (62) Soluble Klotho has been implicated
in Wnt signaling inhibition (63) as well as maintenance of
endothelial integrity (64).
Genetic deletion of Klotho in mice is characterized
by a reduced lifespan, osteoporosis, arteriosclerosis,
hyperphosphatemia, and ectopic calcification (65), hallmarks
of CKD. Indeed, downregulation of Klotho is observed in
CKD patients as well as in animal models of CKD (66–68).
Interestingly, targeted deletion of Klotho in the murine kidney
mimics the phenotype of the full body knockout mice (69).
Taken together, these observations hence point to the kidney
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as the main producer and effector of Klotho in VC. However,
transgenic overexpression of Klotho prevents CKD-induced
medial calcification despite only modest serum phosphate
reduction (67), suggesting that Klotho can also prevent medial
calcification through alternative mechanisms other than
reducing phosphate. Moreover, as mentioned previously, Klotho
can act as an endocrine factor. This is further supported by the
stable delivery of soluble Klotho to Klotho-deficient mice, which
prevents VC despite a modest decrease in serum phosphate and
an increase in serum calcium (70). In support of direct effects
of Klotho in the vascular wall, treatment of rat VSMCs with
recombinant soluble Klotho reduces both phosphate-induced
calcification and sodium-dependent phosphate uptake (67).
However, it is still debated if Klotho is endogenously produced
by VSMCs (71). Therefore, whether these effects on VC are the
consequence of circulating or locally produced Klotho remains
unknown.
Two mutations in the αKLOTHO gene have been described
in humans, which resemble the observed phenotype in mice.
First, a homozygous missense mutation leading to an attenuated
production of Klotho translated in hyperphosphatemia,
hypercalcemia, and both vascular and ectopic calcification in
the brain and the Achilles tendon (72). Second, a balanced
chromosomal translocation in the proximity of the αKLOTHO
gene resulted conversely in increased soluble Klotho levels,
leading to hypophosphatemic rickets and skeletal abnormalities
(73). In CKD, serum Klotho levels decrease alongside disease
progression (74, 75). Moreover, in a small group of patients,
urinary Klotho was decreased in stage 1 CKD patients, and
the decrease correlated with the severity of the decline of
the estimated glomerular filtration rate (67). However, in a
prospective observational study of stage 2–4 CKD patients
circulating Klotho levels did not predict atherosclerotic or
acute heart failure events or death after 2.6 years of follow-up
(76). It is worth noting that none of these studies explored the
relationship between Klotho and VC. Nonetheless, decreased
levels of circulating serum Klotho have been associated with
increased arterial stiffness (77). In summary, serum and urinary
Klotho could hence serve as predictors of CKD progression but
not mortality, whereas their role as biomarkers for VC remains
to be established.
OSTEOPONTIN
Osteopontin (OPN) is a member of the SIBLING (small integrin-
binding ligand, N-linked glycoprotein) protein family of bone
and teeth mineralization regulators (78). It is a multifunctional
protein with a clear role in opsonization and chemotaxis via
integrin signaling in non-mineralized tissues and is highly
expressed by a variety of cell types including macrophages where
it acts as a cytokines (79). Besides these roles, OPN was also one
of the earliest regulators of mineralization identified in the vessel
wall, although its mechanisms of action in regulating VC still
remain incompletely resolved.
Independent studies identified OPN as a protein highly
expressed in synthetic VSMCs in culture and subsequent studies
in vivo identified OPN invariably at sites of mineralization in
both atherosclerotic plaques and the vessel media (80–82). OPN.
When expressed at sites of calcification, it forms a bridging
protein that links the cellular extracellular matrix with mineral.
It may also play a role in the dissolution of calcification by
inducing macrophages to express carbonic anhydrase, which acts
to acidify the local environment (83). Knockout mouse studies
have shown that OPN is not an endogenous inhibitor of VC,
as Opn-deficient mice do not develop spontaneous calcification,
which is consistent with its low expression in contractile VSMCs
(80, 82, 84). However, when Opn-deficient mice are crossed with
Mgp-deficient mice or are subjected to a high phosphate diet,
then calcification is exacerbated, suggesting that OPN functions
as an inducible inhibitor of calcification (84, 85).
OSTEOPROTEGERIN
Osteoprotegerin (OPG) is a protein endogenously expressed by
contractile VSMCs. Its role in calcification was first identified
when the Opg-knockout mouse was found to develop not only
osteoporosis, but also VC and this was one of the first pathways
linking these two age-associated pathologies (86). OPG acts as a
neutralizing decoy receptor for RANKL and TRAIL and it has
a major function in regulating osteoclast differentiation via this
pathway (87). Mice lacking OPG develop osteoporosis because
of increased osteoclast activity–however, the role of OPG in
regulating VC has been more problematic to solve. Mouse OPG
knockout studies showed that in the vessel wall the RANKL
system is activated in the absence of OPG and this is associated
with the presence of multinucleate osteoclast-like cells (88). In
vitro studies have further elaborated the roles of OPG showing it
can affect a number of cell types and processes including blocking
osteoblastic change in VSMCs via direct and paracrine secretion
from endothelial cells and this occurs via multiple signaling
pathways (89, 90). OPG also appears to play an important role
in the context of diabetes by regulating inflammatory responses
(91, 92). Therefore, its actions in protecting the vessel wall from
calcification may be context-dependent and clearly further work
is required to delineate its multifunctional roles. Interestingly,
epidemiological studies have shown that circulating levels of
OPG are increased in patients with VC (93, 94). However,
the significance of this biomarker remains unclear. It is not
known whether its elevation reflects increased OPG to combat
calcification, while the cellular origin of the circulating OPG has
not been identified.
ENDOGENOUS VASCULAR
CALCIFICATION INHIBITOR AS
THERAPEUTIC AGENTS
The use and/or stimulation of the endogenous calcification
inhibitors described herein constitute a tempting therapeutic
strategy. Yet, limited data are available on successful attempts for
the reversal of already established calcification.
The delicate balance of pro-calcifying Pi and the major
anti-calcifying molecule PPi (the Pi/PPi ratio) is regulated
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by numerous factors, opening up for intervention at several
distinct levels. The dietary uptake of Pi can be hindered by
phosphate binders (e.g., sevelamer and aluminum salts) or novel
therapies (e.g., tenapanor), which inhibit Pi absorption from the
gastrointestinal (GI) tract leading to a decreased Pi/PPi ratio.
These molecules are used in hyperphosphatemia in patients
suffering from CKD (95, 96).
Besides decreasing Pi, the Pi/PPi ratio could potentially
be reduced through elevating blood PPi levels. This can
be experimentally achieved via the intraperitoneal or oral
administration of PPi in rodent models, the latter being effective
in humans as well (20, 97, 98). Although oral delivery has clinical
potential as it halts crystal growth in the PXE or progeria mouse
models (97, 98) and prevents calcification even as a gestational
treatment in the GACI mouse model (20), it might have several
limitations. First, only ∼0.1% of dietary PPi is absorbed (20) as
presumably the vast majority of PPi is degraded in the GI tract by
the microbiome. Second, dietary PPi and Pi intake are variable
particularly as PPi is a frequently used food additive (E450).
Additionally, considering the short half-life of PPi in plasma,
several daily doses of PPi might be necessary, although repetitive
administration of PPi might lead to GI and other side effects
(19, 20). Therefore, maintaining sufficient Pi/PPi plasma levels
might be difficult to obtain via oral administration. However,
analogs of PPi, the bisphosphonates, are already in clinical use
for the treatment of osteoporosis, despite the rare but severe
adverse effects (e.g., jaw necrosis). Moreover, bisphosphonates
have been shown to reduce ectopic calcification in patients with
GACI (99, 100) or PXE (101), and in animal models of PXE and
CKD (17, 97, 102).
Besides direct administration of PPi or uncleavable
derivatives, alternative strategies could target endogenous
enzymes involved in the maintenance of PPi concentration. The
serum PPi level can thus be increased by the recombinant soluble
Enpp1 enzyme, as shown in laboratory conditions (103). Finally,
a novel promising target is TNAP, which cleaves PPi into two Pi
ions increasing thereby the Pi/PPi ratio and the propensity for
calcification (104, 105). SBI-425 is a recently developed specific
TNAP inhibitor (106), with sufficient oral bioavailability and
efficacy in mouse models (103–105, 107).
CONSENSUS STATEMENTS
Endogenous calcification inhibitors represent a crucial defense
mechanism against VC. Although the function of the endogenous
VC inhibitors has been extensively studied, there are still
some important clues lacking to fully elucidate their role
in the development of VC. To attain this knowledge, the
EuroSoftCalcNet COST Action consortium here emphasizes the
following:
1. The deep phenotyping of genetic alterations in calcification
inhibitor pathways in both humans and mice represents a
powerful tool to better define their clinical and therapeutic
relevance and to increase our understanding of the alteration
of the pro- and anti-calcifying balance during different stages
of VC and the influence of local and systemic inhibitors on
the cellular response of VSMCs and/or the physical-chemical
properties of mineral deposit.
2. The calcification inhibitors need to be studied from an
integrated point of view, including detailed analysis of the
molecular pathways and the interactions involved, the relation
to altered phosphate (Pi/PPi) balance and the association
with different calcification phenotypes. Altogether, this would
help identify an ideal biomarker measure that should reflect
calcification homeostasis beyond single factors.
3. The central role of the Pi/PPi ratio in the regulation of VC
makes PPi an interesting candidate as an effective and low-cost
treatment against VC.
4. The exploration of the therapeutic potential of PPi and
other calcification inhibitors should focus on bioavailability
and tolerability as well as efforts to avoid bone loss as a
consequence of stimulating these pathways within a long-term
treatment perspective.
AUTHOR CONTRIBUTIONS
All authors listed significantly participated in the content and
writing of the article. MB and HK contributed to the conception
of the article, and to the writing, reviewing, and editing of the
manuscript.
FUNDING
This work was supported by the COST action CA16115
EuroSoftCalcNet.
ACKNOWLEDGMENTS
We thank COST organization for their support and all the
members of our COST action as well as Patients’ associations.
REFERENCES
1. Rashdan NA, Rutsch F, Kempf H, Varadi A, Leftheriotis G, MacRae
VE. New perspectives on rare connective tissue calcifying diseases.
Curr Opin Pharmacol. (2016) 28:14–23. doi: 10.1016/j.coph.2016.
02.002
2. Fleisch H, Bisaz S. Mechanism of calcification: inhibitory role of
pyrophosphate. Nature (1962) 195:911. doi: 10.1038/195911a0
3. Lomashvili KA, Narisawa S, Millan JL, O’Neill WC.
Vascular calcification is dependent on plasma levels of
pyrophosphate. Kidney Int. (2014) 85:1351–6. doi: 10.1038/ki.
2013.521
4. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in
control of tissue calcification and arthritis. Science (2000) 289:265–70.
doi: 10.1126/science.289.5477.265
5. Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, et al.
ABCC6-mediated ATP secretion by the liver is the main source of
the mineralization inhibitor inorganic pyrophosphate in the systemic
circulation-brief report. Arterioscler Thromb Vasc Biol. (2014) 34:1985–9.
doi: 10.1161/ATVBAHA.114.304017
Frontiers in Cardiovascular Medicine | www.frontiersin.org 5 January 2019 | Volume 5 | Article 196
Bäck et al. Inhibitors of Vascular Calcification
6. Hortells L, Sosa C, Millan A, Sorribas V. Critical parameters of the in vitro
method of vascular smooth muscle cell calcification. PLoS ONE (2015)
10:e0141751. doi: 10.1371/journal.pone.0141751
7. O’Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int.
(2007) 72:792–6. doi: 10.1038/sj.ki.5002412
8. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on
hydroxyapatite and its implications in calcium homeostasis. Nature (1966)
212:901–3. doi: 10.1038/212901a0
9. Lomashvili KA, Khawandi W, O’Neill WC. Reduced plasma pyrophosphate
levels in hemodialysis patients. J Am Soc Nephrol. (2005) 16:2495–500.
doi: 10.1681/ASN.2004080694
10. Sheen CR, Kuss P, Narisawa S, Yadav MC, Nigro J, Wang W, et al.
Pathophysiological role of vascular smooth muscle alkaline phosphatase
in medial artery calcification. J Bone Miner Res. (2015) 30:824–36.
doi: 10.1002/jbmr.2420
11. Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC. Upregulation of
alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism
for uremic vascular calcification. Kidney Int. (2008) 73:1024–30.
doi: 10.1038/ki.2008.26
12. Hortells L, Sosa C, Guillen N, Lucea S, Millan A, Sorribas V. Identifying early
pathogenic events during vascular calcification in uremic rats. Kidney Int.
(2017) 92:1384–94. doi: 10.1016/j.kint.2017.06.019
13. Jansen RS, Kucukosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman
IE, et al. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma
elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci USA.
(2013) 110:20206–11. doi: 10.1073/pnas.1319582110
14. Kauffenstein G, Pizard A, Le Corre Y, Vessieres E, Grimaud L, Toutain
B, et al. Disseminated arterial calcification and enhanced myogenic
response are associated with abcc6 deficiency in a mouse model of
pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol. (2014) 34:1045–
56. doi: 10.1161/ATVBAHA.113.302943
15. Mackenzie NC, Zhu D, Milne EM, van’t Hof R, Martin A, Darryl
Quarles L, et al. Altered bone development and an increase in
FGF-23 expression in Enpp1(-/-) mice. PLoS ONE (2012) 7:e32177.
doi: 10.1371/journal.pone.0032177
16. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S. Mutation
in Npps in a mouse model of ossification of the posterior longitudinal
ligament of the spine. Nat Genet. (1998) 19:271–3. doi: 10.1038/956
17. Li Q, Sundberg JP, Levine MA, Terry SF, Uitto J. The effects
of bisphosphonates on ectopic soft tissue mineralization caused
by mutations in the ABCC6 gene. Cell Cycle (2015) 14:1082–9.
doi: 10.1080/15384101.2015.1007809
18. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan
JL. Concerted regulation of inorganic pyrophosphate and osteopontin
by akp2, enpp1, and ank: an integrated model of the pathogenesis
of mineralization disorders. Am J Pathol. (2004) 164:1199–209.
doi: 10.1016/S0002-9440(10)63208-7
19. O’Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL.
Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney
Int. (2011) 79:512–7. doi: 10.1038/ki.2010.461
20. Dedinszki D, Szeri F, Kozak E, Pomozi V, Tokesi N, Mezei TR, et al. Oral
administration of pyrophosphate inhibits connective tissue calcification.
EMBOMol Med. (2017) 9:1463–70. doi: 10.15252/emmm.201707532
21. Cancela ML, Conceicao N, Laize V. Gla-rich protein, a new player in tissue
calcification? Adv Nutr. (2012) 3:174–81. doi: 10.3945/an.111.001685
22. Cancela ML, Laize V, Conceicao N. Matrix Gla protein and osteocalcin:
from gene duplication to neofunctionalization.Arch Biochem Biophys. (2014)
561:56–63. doi: 10.1016/j.abb.2014.07.020
23. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH,
Landewe RB, et al. Characterization and potential diagnostic value of
circulating matrix Gla protein (MGP) species. Thromb Haemost. (2010)
104:811–22. doi: 10.1160/TH09-11-0786
24. Cranenburg EC, Vermeer C, Koos R, BoumansML, Hackeng TM, Bouwman
FG, et al. The circulating inactive form of matrix Gla Protein (ucMGP) as
a biomarker for cardiovascular calcification. J Vasc Res. (2008) 45:427–36.
doi: 10.1159/000124863
25. Boraldi F, Garcia-Fernandez M, Paolinelli-Devincenzi C, Annovi
G, Schurgers L, Vermeer C, et al. Ectopic calcification in beta-
thalassemia patients is associated with increased oxidative stress and
lower MGP carboxylation. Biochim Biophys Acta (2013) 1832:2077–84.
doi: 10.1016/j.bbadis.2013.07.017
26. Gheduzzi D, Boraldi F, Annovi G, DeVincenzi CP, Schurgers LJ, Vermeer C,
et al. Matrix Gla protein is involved in elastic fiber calcification in the dermis
of pseudoxanthoma elasticum patients. Lab Invest. (2007) 87:998–1008.
doi: 10.1038/labinvest.3700667
27. Vanakker OM, Martin L, Schurgers LJ, Quaglino D, Costrop L, Vermeer
C, et al. Low serum vitamin K in PXE results in defective carboxylation
of mineralization inhibitors similar to the GGCX mutations in the PXE-
like syndrome. Lab Invest. (2010) 90:895–905. doi: 10.1038/labinvest.
2010.68
28. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al.
Spontaneous calcification of arteries and cartilage in mice lacking matrix
GLA protein. Nature (1997) 386:78–81. doi: 10.1038/386078a0
29. Khosroshahi HE, Sahin SC, Akyuz Y, Ede H. Long term follow-up of four
patients with Keutel syndrome. Am J Med Genet A (2014) 164A:2849–56.
doi: 10.1002/ajmg.a.36699
30. Marulanda J, Eimar H, McKee MD, Berkvens M, Nelea V, Roman H, et al.
Matrix Gla protein deficiency impairs nasal septum growth, causing midface
hypoplasia. J Biol Chem. (2017) 292:11400–12. doi: 10.1074/jbc.M116.769802
31. Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel
B, et al. Mutations in the gene encoding the human matrix Gla protein cause
Keutel syndrome. Nat Genet. (1999) 21:142–4. doi: 10.1038/5102
32. Bjorklund G, Svanberg E, Dadar M, Card DJ, Chirumbolo S, Harrington DJ,
et al. The role of matrix Gla protein (MGP) in vascular calcification. Curr
Med Chem. (2018) doi: 10.2174/0929867325666180716104159. [Epub ahead
of print].
33. Kaartinen MT, Murshed M, Karsenty G, McKee MD. Osteopontin
upregulation and polymerization by transglutaminase 2 in calcified arteries
of Matrix Gla protein–deficient mice. J Histochem Cytochem. (2007) 55:375–
86. doi: 10.1369/jhc.6A7087.2006
34. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns
EJ, et al. The circulating inactive form of matrix gla protein is a surrogate
marker for vascular calcification in chronic kidney disease: a preliminary
report. Clin J Am Soc Nephrol. (2010) 5:568–75. doi: 10.2215/CJN.070
81009
35. van den Heuvel EG, van Schoor NM, Lips P, Magdeleyns EJ, Deeg DJ,
Vermeer C, et al. Circulating uncarboxylated matrix Gla protein, a marker of
vitamin K status, as a risk factor of cardiovascular disease. Maturitas (2014)
77:137–41. doi: 10.1016/j.maturitas.2013.10.008
36. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, et al.
Undercarboxylated matrix Gla protein is associated with indices of heart
failure and mortality in symptomatic aortic stenosis. J Intern Med. (2010)
268:483–92. doi: 10.1111/j.1365-2796.2010.02264.x
37. Bordoloi J, Dihingia A, Kalita J, Manna P. Implication of a novel vitamin
K dependent protein, GRP/Ucma in the pathophysiological conditions
associated with vascular and soft tissue calcification, osteoarthritis,
inflammation, and carcinoma. Int J Biol Macromol. (2018) 113:309–16.
doi: 10.1016/j.ijbiomac.2018.02.150
38. Willems BA, Furmanik M, Caron MMJ, Chatrou MLL, Kusters DHM,
Welting TJM, et al. Ucma/GRP inhibits phosphate-induced vascular smooth
muscle cell calcification via SMAD-dependent BMP signalling. Sci Rep.
(2018) 8:4961. doi: 10.1038/s41598-018-23353-y
39. Eitzinger N, Surmann-Schmitt C, Bosl M, Schett G, Engelke K, Hess A, et al.
Ucma is not necessary for normal development of the mouse skeleton. Bone
(2012) 50:670–80. doi: 10.1016/j.bone.2011.11.017
40. Pedersen KO. Fetuin, a new globulin isolated from serum. Nature (1944)
154:575. doi: 10.1038/154575a0
41. Heremans JF. Les Globulines Sérique du Systéme Gamma. Brussels: Arscia
(1960).
42. Schmid K, Burgi W. Preparation and properties of the human plasma
Ba-alpha2-glycoproteins. Biochim Biophys Acta (1961) 47:440–53.
doi: 10.1016/0006-3002(61)90539-X
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 January 2019 | Volume 5 | Article 196
Bäck et al. Inhibitors of Vascular Calcification
43. Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, et al.
Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-
A. Formation of colloidal calciprotein particles. J Biol Chem. (2003)
278:13333–41. doi: 10.1074/jbc.M210868200
44. Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, Schafer C, et al.
Hierarchical role of fetuin-A and acidic serum proteins in the formation and
stabilization of calcium phosphate particles. J Biol Chem. (2008) 283:14815–
25. doi: 10.1074/jbc.M709938200
45. Heiss A, Jahnen-Dechent W, Endo H, Schwahn D. Structural dynamics
of a colloidal protein-mineral complex bestowing on calcium phosphate
a high solubility in biological fluids. Biointerphases (2007) 2:16–20.
doi: 10.1116/1.2714924
46. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-
Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits
apatite formation in vitro and in mineralizing calvaria cells. A possible
role in mineralization and calcium homeostasis. J Biol Chem. (1996) 271:20
789–96.
47. Wald J, Wiese S, Eckert T, Jahnen-Dechent W, Richtering W, Heiss A.
Formation and stability kinetics of calcium phosphate–fetuin-A colloidal
particles probed by time-resolved dynamic light scattering. Soft Matter
(2011) 7:2869–74. doi: 10.1039/c0sm01191f
48. Holt SG, Smith ER. Fetuin-A-containing calciprotein particles in mineral
trafficking and vascular disease. Nephrol Dial Transplant. (2016) 31:1583–7.
doi: 10.1093/ndt/gfw048
49. Smith ER, Hewitson TD, Cai MMX, Aghagolzadeh P, Bachtler M,
Pasch A, et al. A novel fluorescent probe-based flow cytometric assay
for mineral-containing nanoparticles in serum. Sci Rep. (2017) 7:5686.
doi: 10.1038/s41598-017-05474-y
50. Miura Y, Iwazu Y, Shiizaki K, Akimoto T, Kotani K, Kurabayashi M,
et al. Identification and quantification of plasma calciprotein particles with
distinct physical properties in patients with chronic kidney disease. Sci Rep.
(2018) 8:1256. doi: 10.1038/s41598-018-19677-4
51. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al.
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a
systemically acting inhibitor of ectopic calcification. J Clin Invest. (2003)
112:357–66. doi: 10.1172/JCI17202
52. Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J,
Salier JP. The inflammation-induced down-regulation of plasma Fetuin-A
(alpha2HS-Glycoprotein) in liver results from the loss of interaction between
long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res.
(2003) 31:5957–70. doi: 10.1093/nar/gkg788
53. Jensen MK, Jensen RA, Mukamal KJ, Guo X, Yao J, Sun Q, et al. Detection
of genetic loci associated with plasma fetuin-A: a meta-analysis of genome-
wide association studies from the CHARGE Consortium. Hum Mol Genet.
(2017) 26:2156–63. doi: 10.1093/hmg/ddx091
54. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm
R, et al. Association of low fetuin-A (AHSG) concentrations in serum with
cardiovascular mortality in patients on dialysis: a cross-sectional study.
Lancet (2003) 361:827–33. doi: 10.1016/S0140-6736(03)12710-9
55. Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, et al. Fetuin-
mineral complex reflects extraosseous calcification stress in CKD. J Am Soc
Nephrol. (2010) 21:1998–2007. doi: 10.1681/ASN.2009090944
56. Pasch A. Novel assessments of systemic calcification propensity.
Curr Opin Nephrol Hypertens. (2016) 25:278–84. doi: 10.1097/MNH.
0000000000000237
57. Dahle DO, Asberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG,
et al. Serum calcification propensity is a strong and independent determinant
of cardiac and all-cause mortality in kidney transplant recipients. Am J
Transplant. (2016) 16:204–12. doi: 10.1111/ajt.13443
58. Keyzer CA, de Borst MH, van den Berg E, Jahnen-Dechent W,
Arampatzis S, Farese S, et al. Calcification propensity and survival
among renal transplant recipients. J Am Soc Nephrol. (2016) 27:239–48.
doi: 10.1681/ASN.2014070670
59. Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis
S, et al. Blood calcification propensity, cardiovascular events, and survival in
patients receiving hemodialysis in the evolve trial. Clin J Am Soc Nephrol.
(2017) 12:315–22. doi: 10.2215/CJN.04720416
60. Pasch A, Farese S, Graber S, Wald J, Richtering W, Floege J, et al.
Nanoparticle-based test measures overall propensity for calcification in
serum. J Am Soc Nephrol. (2012) 23:1744–52. doi: 10.1681/ASN.2012030240
61. Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S,
et al. Serum calcification propensity predicts all-causemortality in predialysis
CKD. J Am Soc Nephrol. (2014) 25:339–48. doi: 10.1681/ASN.2013060635
62. Mencke R, Hillebrands JL, consortium N. The role of the anti-ageing protein
Klotho in vascular physiology and pathophysiology. Ageing Res Rev. (2017)
35:124–46. doi: 10.1016/j.arr.2016.09.001
63. Satoh M, Nagasu H, Morita Y, Yamaguchi TP, Kanwar YS, Kashihara
N. Klotho protects against mouse renal fibrosis by inhibiting
Wnt signaling. Am J Physiol Renal Physiol. (2012) 303:F1641–51.
doi: 10.1152/ajprenal.00460.2012
64. Kusaba T, Okigaki M, Matui A, Murakami M, Ishikawa K, Kimura T,
et al. Klotho is associated with VEGF receptor-2 and the transient receptor
potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc
Natl Acad Sci USA. (2010) 107:19308–13. doi: 10.1073/pnas.1008544107
65. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al.
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
Nature (1997) 390:45–51. doi: 10.1038/36285
66. Aizawa H, Saito Y, Nakamura T, Inoue M, Imanari T, Ohyama Y,
et al. Downregulation of the Klotho gene in the kidney under sustained
circulatory stress in rats. Biochem Biophys Res Commun. (1998) 249:865–71.
doi: 10.1006/bbrc.1998.9246
67. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, et al. Klotho
deficiency causes vascular calcification in chronic kidney disease. J Am Soc
Nephrol. (2011) 22:124–36. doi: 10.1681/ASN.2009121311
68. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T,
et al. Severely reduced production of klotho in human chronic renal
failure kidney. Biochem Biophys Res Commun. (2001) 280:1015–20.
doi: 10.1006/bbrc.2000.4226
69. Lindberg K, Amin R, Moe OW, Hu MC, Erben RG, Ostman Wernerson A,
et al. The kidney is the principal organ mediating klotho effects. J Am Soc
Nephrol. (2014) 25:2169–75. doi: 10.1681/ASN.2013111209
70. Hum JM, O’Bryan LM, Tatiparthi AK, Cass TA, Clinkenbeard EL, Cramer
MS, et al. Chronic hyperphosphatemia and vascular calcification are reduced
by stable delivery of soluble klotho. J Am Soc Nephrol. (2017) 28:1162–74.
doi: 10.1681/ASN.2015111266
71. Yamada S, Giachelli CM. Vascular calcification in CKD-MBD:
roles for phosphate, FGF23, and klotho. Bone (2017) 100:87–93.
doi: 10.1016/j.bone.2016.11.012
72. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, et al. A
homozygous missense mutation in human KLOTHO causes severe tumoral
calcinosis. J Clin Invest. (2007) 117:2684–91. doi: 10.1172/JCI31330
73. Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A,
et al. A translocation causing increased alpha-klotho level results in
hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci
USA. (2008) 105:3455–60. doi: 10.1073/pnas.0712361105
74. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, et al. Circulating
alpha-klotho levels in CKD and relationship to progression.Am J Kidney Dis.
(2013) 61:899–909. doi: 10.1053/j.ajkd.2013.01.024
75. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, et al. Secreted
Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence
suggested from a cross-sectional study. Nephrol Dial Transplant. (2013)
28:352–9. doi: 10.1093/ndt/gfs460
76. Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al.
Associations of FGF-23 and sKlotho with cardiovascular outcomes among
patients with CKD stages 2-4. Clin J Am Soc Nephrol. (2014) 9:1049–58.
doi: 10.2215/CJN.07870713
77. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A,
et al. A decreased level of serum soluble Klotho is an independent
biomarker associated with arterial stiffness in patients with chronic
kidney disease. PLoS ONE (2013) 8:e56695. doi: 10.1371/journal.pone.00
56695
78. Staines KA, MacRae VE, Farquharson C. The importance of the SIBLING
family of proteins on skeletal mineralisation and bone remodelling. J
Endocrinol. (2012) 214:241–55. doi: 10.1530/JOE-12-0143
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 January 2019 | Volume 5 | Article 196
Bäck et al. Inhibitors of Vascular Calcification
79. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule
regulating chronic inflammation and vascular disease. Arterioscler Thromb
Vasc Biol. (2007) 27:2302–9. doi: 10.1161/ATVBAHA.107.144824
80. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM.
Osteopontin is elevated during neointima formation in rat arteries and is
a novel component of human atherosclerotic plaques. J Clin Invest. (1993)
92:1686–96. doi: 10.1172/JCI116755
81. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of
genes for calcification-regulating proteins in human atherosclerotic plaques.
J Clin Invest. (1994) 93:2393–402. doi: 10.1172/JCI117246
82. Shanahan CM, Weissberg PL, Metcalfe JC. Isolation of gene markers of
differentiated and proliferating vascular smoothmuscle cells.Circ Res. (1993)
73:193–204. doi: 10.1161/01.RES.73.1.193
83. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang
H, et al. Osteopontin inhibits mineral deposition and promotes
regression of ectopic calcification. Am J Pathol. (2002) 161:2035–46.
doi: 10.1016/S0002-9440(10)64482-3
84. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, et al.
Inactivation of the osteopontin gene enhances vascular calcification of
matrix Gla protein-deficient mice: evidence for osteopontin as an inducible
inhibitor of vascular calcification in vivo. J Exp Med. (2002) 196:1047–55.
doi: 10.1084/jem.20020911
85. Paloian NJ, Leaf EM, Giachelli CM. Osteopontin protects against high
phosphate-induced nephrocalcinosis and vascular calcification. Kidney Int.
(2016) 89:1027–36. doi: 10.1016/j.kint.2015.12.046
86. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial
calcification. Genes Dev. (1998) 12:1260–8. doi: 10.1101/gad.12.9.1260
87. Collin-Osdoby P. Regulation of vascular calcification by osteoclast
regulatory factors RANKL and osteoprotegerin. Circ Res. (2004) 95:1046–57.
doi: 10.1161/01.RES.0000149165.99974.12
88. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S,
et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal
osteoclasts and prevents vascular calcification by blocking a process
resembling osteoclastogenesis. J Exp Med. (2000) 192:463–74.
doi: 10.1084/jem.192.4.463
89. Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M. Increased
calcification in osteoprotegerin-deficient smooth muscle cells: dependence
on receptor activator of NF-kappaB ligand and interleukin 6. J Vasc Res.
(2014) 51:118–31. doi: 10.1159/000358920
90. Di Bartolo BA, Kavurma MM. Regulation and function of Rankl
in arterial calcification. Curr Pharm Des. (2014) 20:5853–61.
doi: 10.2174/1381612820666140212205455
91. Ndip A, Wilkinson FL, Jude EB, Boulton AJ, Alexander MY.
RANKL-OPG and RAGE modulation in vascular calcification and
diabetes: novel targets for therapy. Diabetologia (2014) 57:2251–60.
doi: 10.1007/s00125-014-3348-z
92. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth
JV, et al. The RANKL/RANK/OPG signaling pathway mediates medial
arterial calcification in diabetic Charcot neuroarthropathy. Diabetes (2011)
60:2187–96. doi: 10.2337/db10-1220
93. Siasos G, Oikonomou E, Maniatis K, Georgiopoulos G, Kokkou E, Tsigkou
V, et al. Prognostic significance of arterial stiffness and osteoprotegerin
in patients with stable coronary artery disease. Eur J Clin Invest. (2018)
48:e12890. doi: 10.1111/eci.12890
94. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin
as a predictor of coronary artery disease and cardiovascular
mortality and morbidity. J Am Coll Cardiol. (2010) 55:2049–61.
doi: 10.1016/j.jacc.2010.03.013
95. King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al. Inhibition
of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor
reduces paracellular phosphate permeability. Sci Transl Med. (2018)
10:eaam6474. doi: 10.1126/scitranslmed.aam6474
96. Vo TM, Disthabanchong S. Are there ways to attenuate arterial calcification
and improve cardiovascular outcomes in chronic kidney disease? World J
Cardiol. (2014) 6:216–26. doi: 10.4330/wjc.v6.i5.216
97. Pomozi V, Brampton C, van de Wetering K, Zoll J, Calio B, Pham
K, et al. Pyrophosphate supplementation prevents chronic and acute
calcification in ABCC6-deficient mice. Am J Pathol. (2017) 187:1258–72.
doi: 10.1016/j.ajpath.2017.02.009
98. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acin-Perez R, Enriquez
JA, Lopez-Otin C, et al. Defective extracellular pyrophosphate
metabolism promotes vascular calcification in a mouse model
of Hutchinson-Gilford progeria syndrome that is ameliorated
on pyrophosphate treatment. Circulation (2013) 127:2442–51.
doi: 10.1161/CIRCULATIONAHA.112.000571
99. Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf
T, et al. Hypophosphatemia, hyperphosphaturia, and bisphosphonate
treatment are associated with survival beyond infancy in generalized
arterial calcification of infancy. Circ Cardiovasc Genet. (2008) 1:133–40.
doi: 10.1161/CIRCGENETICS.108.797704
100. Yapicioglu-Yildizdas H, Ozbarlas N, Erdem S, YilmazMB, Ozlu F, Buyukkurt
S, et al. Two newborn babies with generalized arterial calcification
of infancy, two new mutations. Turk J Pediatr. (2016) 58:419–23.
doi: 10.24953/turkjped.2016.04.013
101. Kranenburg G, de Jong PA, Bartstra JW, Lagerweij SJ, LamMG, Ossewaarde-
van Norel J, et al. Etidronate for prevention of ectopic mineralization in
patients with pseudoxanthoma elasticum. J AmColl Cardiol. (2018) 71:1117–
26. doi: 10.1016/j.jacc.2017.12.062
102. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O’Neill
WC. Effect of bisphosphonates on vascular calcification and bone
metabolism in experimental renal failure. Kidney Int. (2009) 75:617–25.
doi: 10.1038/ki.2008.646
103. Albright RA, Stabach P, Cao W, Kavanagh D, Mullen I, Braddock AA, et al.
ENPP1-Fc prevents mortality and vascular calcifications in rodent model of
generalized arterial calcification of infancy. Nat Commun. (2015) 6:10006.
doi: 10.1038/ncomms10006
104. Varadi A, Fulop K, Aranyi T, Szeri F. Tissue-nonspecific alkaline
phosphatase: a promising target for pseudoxanthoma elasticum
therapy. Ann Transl Med. (2017) 5:489. doi: 10.21037/atm.2017.
10.01
105. Ziegler SG, Ferreira CR, MacFarlane EG, Riddle RC, Tomlinson RE, Chew
EY, et al. Ectopic calcification in pseudoxanthoma elasticum responds to
inhibition of tissue-nonspecific alkaline phosphatase. Sci Transl Med. (2017)
9:eaal1669. doi: 10.1126/scitranslmed.aal1669
106. Pinkerton AB, Sergienko E, Bravo Y, Dahl R, Ma CT, Sun Q, et al.
Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide
(SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline
phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett. (2018) 28:31–4.
doi: 10.1016/j.bmcl.2017.11.024
107. Li Q, Huang J, Pinkerton AB, Millan JL, van Zelst BD, Levine MA,
et al. Inhibition of tissue-nonspecific alkaline phosphatase attenuates
ectopic mineralization in the Abcc6(-/-) mouse model of PXE but not
in the Enpp1 mutant mouse models of GACI. J Invest Dermatol. (2018).
doi: 10.1016/j.jid.2018.07.030. [Epub ahead of print].
Conflict of Interest Statement: AP is an inventor of the calcification propensity
(T50) test, and an employee and stockholder in Calciscon AG (Nidau, Switzerland)
which commercializes this blood test.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
The reviewer WJ declared a past co-authorship with one of the authors CS
to the handling editor.
Copyright © 2019 Bäck, Aranyi, Cancela, Carracedo, Conceição, Leftheriotis,
Macrae, Martin, Nitschke, Pasch, Quaglino, Rutsch, Shanahan, Sorribas, Szeri,
Valdivielso, Vanakker and Kempf. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 8 January 2019 | Volume 5 | Article 196
